Advisor Information
SONG-YOUNG PARK
Location
MBSC 201
Presentation Type
Poster
Start Date
6-3-2020 9:00 AM
End Date
6-3-2020 10:15 AM
Abstract
Mild cognitive impairment (MCI) is a decline in cognitive function to a greater extent than natural aging. It has been suggested that reduced brain blood flow is strongly associated with reduced cognitive function and neurodegenerative diseases, of which is partially attributed to excessive reactive oxygen species (ROS) production. Mitoquinol mesylate has been shown to scavenge ROS and improve vascular function in healthy older adults. However, the effects of mitoquinol in MCI patients have not been investigated.
Purpose: to elucidate the impacts of mitoquinol intake on vascular endothelial function (flow-mediated dilation, FMD), arterial stiffness (pulse-wave velocity, PWV), and cognitive function in an MCI patient. We hypothesized that acute mitoquinol intake would improve vascular and cognitive function.
One MCI patient (male, age 84) received mitoquinol and placebo in a crossover design. Vascular and cognitive function measurements were taken pre-and post-mitoquinol intake including endothelial function, arterial stiffness, cognitive function, and central and peripheral BP.
Following mitoquinol ingestion, brachial artery FMD and popliteal artery FMD both increased (D1.6%; D5%) compared to placebo, along with decreased peripheral BP (D0/-8) and central BP (D-9/-8) compared to placebo. There were decreases in carotid-to-radial PWV (D-0.7 m/s) and carotid-to-distal PWV (D-0.4 m/s) compared to placebo. HR did not change following mitoquinol intake, while HR increased following placebo intake (D1).
Our preliminary results demonstrate that mitoquinol may be a potentially useful therapeutic treatment to improve vascular function via endothelial-dependent vasodilatory mechanisms. However, a bigger sample size is warranted to fully elucidate the effects.
IMPACTS OF MITOQUINOL MESYLATE INTAKE ON VASCULAR FUNCTION AND COGNITIVE IMPAIRMENT IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT: A CASE STUDY
MBSC 201
Mild cognitive impairment (MCI) is a decline in cognitive function to a greater extent than natural aging. It has been suggested that reduced brain blood flow is strongly associated with reduced cognitive function and neurodegenerative diseases, of which is partially attributed to excessive reactive oxygen species (ROS) production. Mitoquinol mesylate has been shown to scavenge ROS and improve vascular function in healthy older adults. However, the effects of mitoquinol in MCI patients have not been investigated.
Purpose: to elucidate the impacts of mitoquinol intake on vascular endothelial function (flow-mediated dilation, FMD), arterial stiffness (pulse-wave velocity, PWV), and cognitive function in an MCI patient. We hypothesized that acute mitoquinol intake would improve vascular and cognitive function.
One MCI patient (male, age 84) received mitoquinol and placebo in a crossover design. Vascular and cognitive function measurements were taken pre-and post-mitoquinol intake including endothelial function, arterial stiffness, cognitive function, and central and peripheral BP.
Following mitoquinol ingestion, brachial artery FMD and popliteal artery FMD both increased (D1.6%; D5%) compared to placebo, along with decreased peripheral BP (D0/-8) and central BP (D-9/-8) compared to placebo. There were decreases in carotid-to-radial PWV (D-0.7 m/s) and carotid-to-distal PWV (D-0.4 m/s) compared to placebo. HR did not change following mitoquinol intake, while HR increased following placebo intake (D1).
Our preliminary results demonstrate that mitoquinol may be a potentially useful therapeutic treatment to improve vascular function via endothelial-dependent vasodilatory mechanisms. However, a bigger sample size is warranted to fully elucidate the effects.